Neuraxis

Neuraxis P/TBV

The Price to Tangible Book Value (P/TBV) of Neuraxis (NRXS) as of Nov 22, 2026 is 15.39. In the previous year, Price to Tangible Book Value (P/TBV) was 26.54 — a change of -42.01% (lower).

P/TBV

15.39

YoY

-42.01%

Last updated:

Price to Tangible Book Value (P/TBV) of Neuraxis is 2025 15.39 . Price to Tangible Book Value (P/TBV) of Neuraxis was 2024 26.54 . It decreases by -42.01% lower compared to the previous year.

The Neuraxis P/TBV history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/TBV
Date
P/TBV
Jan 1, 2020
32.41 USD
Jan 1, 2021
-61.85 USD
Jan 1, 2022
-9.25 USD
Jan 1, 2023
-34.61 USD
Jan 1, 2024
26.54 USD
Jan 1, 2025
15.39 USD
The Neuraxis P/TBV history
YEARP/TBVYoY
15.39-42.01%
26.54-176.67%
-34.61+274.08%
-9.25-85.04%
-61.85-290.82%
32.41—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neuraxis Stock analysis

What does Neuraxis do? NeurAxis, Inc. generates revenue through the development and commercialization of neuromodulation therapies targeting chronic conditions in pediatric patients. The company's primary product, the B-Stim device, is designed for functional abdominal pain associated with irritable bowel syndrome (IBS) and functional nausea in children aged 11-18. The FDA pipeline includes additional indications such as chronic nausea, post-concussion syndrome, chemotherapy-induced nausea and vomiting, and cyclic vomiting syndrome, which expand the potential market reach of their PENFS technology. The company's focus on pediatric applications differentiates its offerings within the neuromodulation sector. The Percutaneous Electrical Nerve Field Stimulation (PENFS) technology underpins both the B-Stim and IB-Stim systems, which are specifically tailored for pediatric use. These devices are intended for patients 11-18 years of age with functional abdominal pain linked to IBS, positioning NeurAxis to address unmet medical needs in adolescent healthcare. The FDA's involvement in the pipeline process ensures regulatory alignment for expanding indications, which supports market adoption and potential revenue streams. NeurAxis targets healthcare providers and pediatric specialists who treat chronic conditions in adolescents. The company's products are positioned to address functional gastrointestinal disorders and related symptoms, offering an alternative to traditional pharmacological treatments. By focusing on specific age groups and medical indications, NeurAxis aims to capture a niche segment within the broader neuromodulation market. Neuraxis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neuraxis stock

Price to Tangible Book Value (P/TBV) of Neuraxis is 15.39 in 2025.

Price to Tangible Book Value (P/TBV) of Neuraxis changed from 26.54 to 15.39, representing a -42.01% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Price to Tangible Book Value (P/TBV) Neuraxis since 2006 – with annual values, charts, and detailed analysis.

P/TBV compares the stock price to tangible book value per share, excluding goodwill and intangibles. It provides a conservative asset-based valuation.

To evaluate Price to Tangible Book Value (P/TBV)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Price to Tangible Book Value (P/TBV).

A 'good' varies by industry and company stage. On Eulerpool, you can compare Price to Tangible Book Value (P/TBV)'s Neuraxis with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Neuraxis

All Key Metrics — Neuraxis